docetaxel + prednisone + afuresertib

This drug is a combination of three agents: **docetaxel** (a taxane antineoplastic agent that promotes tubulin polymerization and inhibits microtubule depolymerization, leading to apoptosis of cancer cells), **prednisone** (a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, often included in cancer regimens for symptom management and reduction of chemotherapy side effects), and **afuresertib** (an orally available, ATP-competitive, pan-AKT kinase inhibitor that blocks all three AKT isoforms and inhibits the PI3K/AKT signaling pathway, with antineoplastic activity by inducing apoptosis and blocking tumor cell proliferation)[1][2][4][6]. This combination is being investigated, particularly for prostate cancer, including metastatic castration-resistant prostate cancer, where combination regimens with docetaxel and prednisone represent a standard backbone and the addition of afuresertib provides a targeted approach via AKT pathway inhibition[2]. Afuresertib's developer is Laekna (current), originally developed by GSK[6].